Burgundy Asset Management Ltd. reduced its position in shares of CME Group Inc. (NASDAQ:CME - Free Report) by 9.2% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 613,444 shares of the financial services provider's stock after selling 61,798 shares during the quarter. CME Group comprises about 1.4% of Burgundy Asset Management Ltd.'s portfolio, making the stock its 29th biggest position. Burgundy Asset Management Ltd. owned 0.17% of CME Group worth $142,460,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also bought and sold shares of CME. Koshinski Asset Management Inc. lifted its holdings in CME Group by 3.4% during the fourth quarter. Koshinski Asset Management Inc. now owns 3,474 shares of the financial services provider's stock worth $807,000 after buying an additional 115 shares during the period. Atomi Financial Group Inc. lifted its stake in shares of CME Group by 34.1% during the 4th quarter. Atomi Financial Group Inc. now owns 3,725 shares of the financial services provider's stock worth $865,000 after purchasing an additional 947 shares during the last quarter. MCF Advisors LLC boosted its position in CME Group by 25.6% during the fourth quarter. MCF Advisors LLC now owns 358 shares of the financial services provider's stock valued at $85,000 after purchasing an additional 73 shares in the last quarter. Beaumont Financial Advisors LLC grew its stake in CME Group by 9.6% in the fourth quarter. Beaumont Financial Advisors LLC now owns 2,029 shares of the financial services provider's stock valued at $471,000 after purchasing an additional 177 shares during the last quarter. Finally, Simon Quick Advisors LLC raised its holdings in CME Group by 28.5% in the fourth quarter. Simon Quick Advisors LLC now owns 1,523 shares of the financial services provider's stock worth $354,000 after purchasing an additional 338 shares in the last quarter. 87.75% of the stock is owned by institutional investors.
CME Group Trading Up 0.7%
CME stock traded up $1.91 during mid-day trading on Wednesday, hitting $286.27. 664,913 shares of the company were exchanged, compared to its average volume of 2,324,586. CME Group Inc. has a 12-month low of $190.70 and a 12-month high of $286.80. The business has a fifty day simple moving average of $268.56 and a 200-day simple moving average of $250.00. The firm has a market capitalization of $103.16 billion, a P/E ratio of 29.60, a PEG ratio of 6.76 and a beta of 0.45. The company has a quick ratio of 1.02, a current ratio of 1.01 and a debt-to-equity ratio of 0.10.
CME Group (NASDAQ:CME - Get Free Report) last released its earnings results on Wednesday, April 23rd. The financial services provider reported $2.80 earnings per share for the quarter, topping analysts' consensus estimates of $2.61 by $0.19. CME Group had a net margin of 57.52% and a return on equity of 13.62%. The firm had revenue of $1.64 billion for the quarter, compared to analyst estimates of $1.56 billion. During the same period in the prior year, the firm earned $2.50 earnings per share. The business's quarterly revenue was up 10.4% compared to the same quarter last year. On average, equities research analysts predict that CME Group Inc. will post 10.49 earnings per share for the current fiscal year.
CME Group Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 25th. Shareholders of record on Monday, June 9th will be issued a $1.25 dividend. This represents a $5.00 dividend on an annualized basis and a yield of 1.75%. The ex-dividend date of this dividend is Monday, June 9th. CME Group's dividend payout ratio is presently 50.30%.
Insider Buying and Selling at CME Group
In other CME Group news, insider Hilda Harris Piell sold 3,984 shares of the firm's stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $250.47, for a total transaction of $997,872.48. Following the sale, the insider now directly owns 27,046 shares of the company's stock, valued at $6,774,211.62. This trade represents a 12.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Martin J. Gepsman sold 300 shares of the company's stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $273.17, for a total transaction of $81,951.00. Following the transaction, the director now directly owns 24,767 shares in the company, valued at $6,765,601.39. The trade was a 1.20% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 28,384 shares of company stock valued at $7,531,053. 0.30% of the stock is owned by corporate insiders.
Analyst Upgrades and Downgrades
A number of brokerages have recently issued reports on CME. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $269.00 price objective on shares of CME Group in a research report on Thursday, April 3rd. Raymond James raised shares of CME Group from a "market perform" rating to an "outperform" rating and set a $287.00 price target on the stock in a report on Monday, March 10th. Piper Sandler increased their price objective on CME Group from $275.00 to $283.00 and gave the company an "overweight" rating in a report on Tuesday, April 8th. Oppenheimer increased their price target on CME Group from $269.00 to $279.00 and gave the company an "outperform" rating in a research note on Friday, April 11th. Finally, Morgan Stanley boosted their price target on CME Group from $301.00 to $304.00 and gave the stock an "overweight" rating in a research note on Thursday, April 24th. Three analysts have rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $256.80.
Get Our Latest Analysis on CME Group
About CME Group
(
Free Report)
CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.
Featured Stories

Before you consider CME Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CME Group wasn't on the list.
While CME Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.